<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04121273</url>
  </required_header>
  <id_info>
    <org_study_id>v1.0 20180620</org_study_id>
    <nct_id>NCT04121273</nct_id>
  </id_info>
  <brief_title>GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC</brief_title>
  <official_title>Clinical Study of GPC3-targeted Chimeric Antigen Receptor T Cells fo Treating Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with hepatocellular carcinoma (a type of primary liver cancers) are enrolls in this&#xD;
      study. The cancer has progressed after standard treatment, or the patient cannot receive&#xD;
      regular treatment.&#xD;
&#xD;
      Investigator made a gene called chimeric antigen receptor derived from an antibody that&#xD;
      recognizes Glypican 3, a protein detected in in a large proportion of hepatocellular&#xD;
      carcinoma. The gene will introduce into T cell from patient's blood to make them recognize&#xD;
      and kill cancer cells.&#xD;
&#xD;
      The aim of this study is to evaluate the efficacy, tolerance and safety of chimeric antigen&#xD;
      receptor-modified T (CAR-T) cell targeting Glypican 3 for advanced hepatocellular carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patient with dose limiting toxicity</measure>
    <time_frame>2 months</time_frame>
    <description>After each dose of T cell infusion, the adverse effects related to T cell therapy such as fever and jaundice are observed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiological evaluation of tumor size after CAR- T immunotherapy</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate the therapeutic effect of CAR-T immunotherapy radiological observation of the tumor size after infusion of CAR-T cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral tumor marker</measure>
    <time_frame>3 months</time_frame>
    <description>After CAR-T cell infusion, alpha fetoprotein (AFP) will be tested regularly in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Peripheral CAR-T cell</measure>
    <time_frame>3 months</time_frame>
    <description>The number and proliferation in vivo are tested with Flow Cytometry regularly.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAR-T cells targeting GPC3 will be administered to enrolled patients with hepatocellular carcinoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAR-T cell immunotherapy</intervention_name>
    <description>Patients enrolled will recieve three different doses of the CAR-T cell every two weeks as follows:&#xD;
Dose 1: 1x10^7/m2&#xD;
Dose 2: 3x10^7/m2&#xD;
Dose 3: 1x10^8/m2&#xD;
The cell numbers are calculated according to CAR-positive T cells.</description>
    <arm_group_label>CAR-T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. GPC3 positive HCC, tumor size &gt;= 5 cm, cannot receive standard treatment, Expected&#xD;
             survival time&gt;=3 months.&#xD;
&#xD;
          2. Routine blood test: white blood cell count（WBC)&gt;= 2.5×10^9/L, hemoglobin (Hb)&gt;= 9.0&#xD;
             g/dL, blood platelet &gt;= 60×10^9/L, Lymphocyte percentage&gt;=15%.&#xD;
&#xD;
          3. Blood biochemical parameters: ALB &gt;= 30 g/L, ALT &lt;= 5 times of the normal value, AST&#xD;
             &lt;= 5 times of the normal value, serum lipase&lt;=1.5 times of the normal value, serum&#xD;
             amylase&lt;=1.5 times of the normal value， total bilirubin &lt;= 2.5 times of the normal&#xD;
             value.&#xD;
&#xD;
          4. Prothrombin time INR &lt; 1.7.&#xD;
&#xD;
          5. Ejection fraction (EF) &gt;= 55%, oxygen saturation (SO2) &gt; 90%.&#xD;
&#xD;
          6. No allergic reaction to contrast material.&#xD;
&#xD;
          7. Karnofsky score &gt;= 60%.&#xD;
&#xD;
          8. Child-puge score &lt;7.&#xD;
&#xD;
          9. Peripheral venous access.&#xD;
&#xD;
         10. Voluntarily signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or lactation.&#xD;
&#xD;
          2. Systemic steroid treatment ( &gt;prednisone equivalent/kg/day).&#xD;
&#xD;
          3. Patients with previous history of cell immunotherapy or antibody therapy.&#xD;
&#xD;
          4. Patients received radiotherapy/chemotherapy in the past 4 weeks.&#xD;
&#xD;
          5. Patients are participating in other clinical trials.&#xD;
&#xD;
          6. Patients with uncontrolled symptoms including infection, heart failure, arrhythmia.&#xD;
&#xD;
          7. Patients with acute allergic reaction.&#xD;
&#xD;
          8. History of liver transplantation.&#xD;
&#xD;
          9. Patients with anticoagulant treatment.&#xD;
&#xD;
         10. Patients with hepatic encephalopathy.&#xD;
&#xD;
         11. Eligible for hepatectomy, liver transplantation or other standard treatment.&#xD;
&#xD;
         12. Unstable gastrointestinal and respiratory bleeding.&#xD;
&#xD;
         13. Active viral, fungal or bacterial infections.&#xD;
&#xD;
         14. Heart failure classification (NYHA): II-IV.&#xD;
&#xD;
         15. Patients are unable or unwilling to comply with the requirements of the study&#xD;
             protocol.&#xD;
&#xD;
         16. Patients do not meet the criteria above.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Decai Yu, MD</last_name>
    <phone>8613701585023</phone>
    <email>yudecai@nju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenfang Tian, PhD</last_name>
    <phone>8613675104348</phone>
    <email>tiancpu@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenfang Tian, PhD</last_name>
      <phone>8613675104348</phone>
      <email>tiancpu@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Beicheng Sun</investigator_full_name>
    <investigator_title>Director of Hepatobiliary Surgery</investigator_title>
  </responsible_party>
  <keyword>chimeric antigen receptor T cell (CAR- T)</keyword>
  <keyword>glypican-3 (GPC3)</keyword>
  <keyword>hepatocellular carcinoma (HCC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

